医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Guided Therapeutics Awarded Multiple Tenders for LuViva® Advanced Cervical Scan Systems from Governments in Bangladesh

2015年06月04日 PM09:30
このエントリーをはてなブックマークに追加


 

DHAKA, Bangladesh

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that its distributor in Bangladesh has been awarded contracts for four additional LuViva® Advanced Cervical Scan systems for use in the country’s cervical cancer screening program. The latest awards double the number of LuViva units purchased by various government agencies in Bangladesh to eight.

“Governments around the world, like Bangladesh, are taking serious notice of the LuViva and its ability to deliver the highest level of modern cervical cancer screening to women, particularly in countries without the expensive infrastructure needed to support traditional screening and diagnostics,” said Gene Cartwright, CEO of Guided Therapeutics. “Increasing purchases of LuViva by governments in Asia, Africa and Latin America validate the high demand potential for the product as a primary screener for cervical cancer in the developing world. We expect demand to be significantly higher compared to countries that are using LuViva as a triage device to lower costs and identify false positives caused by the Pap test used in conventional screening programs.”

In Bangladesh, where cervical cancer is the leading cancer among women, the screening-age population is estimated to be 38 million. World-wide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. Worldwide there are about 1.7 billion women of screening ages 25 to 64.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and “Early detection, better outcomes” are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent filings.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150604005645/en/

CONTACT

Guided Therapeutics
Bill Wells, 770-242-8723
or
Investors:
Cameron
Associates
Alison Ziegler, 212-554-5469

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia